Novo Nordisk partners with Vivtex in a $2.1 billion deal to enhance oral biologic drug delivery, targeting obesity treatment advancements.
Author: PharmaSignal News Desk
Vir Astellas T Cell Engager shows promise in oncology, with early data validating Vir’s shift from infectious diseases.
FDA draft guidance aims to accelerate the development of personalized therapies for rare diseases, impacting over 7,000 conditions.
Merck restructuring involves creating a standalone cancer unit and a second business for other drugs, impacting Keytruda’s future.
Roche FDA decision on Giredestrant expected by December 2023, potentially setting a new standard for breast cancer treatment.
PharmaSignal Take This week’s events signal a strong push for strategic alliances and acquisitions, with Lilly’s notable deals and investments in genetic medicine and monoclonal antibodies. These moves stress-test the assumption of platform scalability and highlight the importance of post-approval decision-making in the context of regulatory hurdles and market access. In this PharmaSignal Weekly Brief – Global Pharma Roundup, we observe a surge in M&A activity, regulatory challenges, and pipeline advancements, providing a comprehensive view of the current pharma landscape. M&A and Strategic Deals Lilly’s acquisition of Orna for $2.4 billion and its $9 billion alliance with Innovent Biologics underscore…
Lilly CSL $100M deal involves licensing a monoclonal antibody targeting IL-6, with CSL retaining rights for end-stage kidney disease.
BMS FDA Review: The FDA has accepted BMS’s protein degrader for review, potentially impacting the US market with new treatment options.
Moderna FDA review progresses for mRNA flu vaccine after a Type A meeting, impacting the US market.
COMP360 psilocybin FDA application progresses with Phase 3 data, aiming to be the first classic psychedelic approved in the U.S.